(Boston, June 2017) – Boston Strategic Partners supported SAGE Therapeutics in the creation of an article recently published in The Lancet online. The article titled “Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial” was a Phase 2, double-blind, randomized and placebo-controlled study of brexanolone (USAN: formerly SAGE-547 injection) in women with severe postpartum depression (PPD). Post-partum depression is a serious mood disorder in women and the most common medical complication of childbearing. The study found that treatment with brexanolone resulted in significant and clinically meaningful reductions in depression as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D).
Founded in 2003, Boston Strategic Partners, Inc. is a dedicated healthcare and life sciences company. We offer five different types of services:
- Business & Clinical Strategy
- Health Economics & Outcomes Research (HEOR)
- Medical Communications
- Regulatory Strategy
- Financial Advisory
For more information or to schedule a meeting with our team, please email us at email@example.com
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage’s lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.